5:53 PM
 | 
Jul 12, 2012
 |  BC Extra  |  Top Story

Verastem unveils new pipeline

Since its $55 million IPO in January, cancer stem cell company Verastem Inc. (NASDAQ:VSTM) has revamped its pipeline through three deals, according to a pipeline update released Thursday. Verastem said it postponed development of its preclinical Wnt inhibitor VS-507, which was one of the company's lead programs at the time of its IPO, and...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >